With the research field still in its infancy, the first clinical application of the PSMA-11-derived peptidomimetic PSMA-targeting molecule PSMA-914 already highlights the great future potential of targeted hybrid agents in the surgical treatment of prostate cancer patients and emphasizes the urgent need for further preclinical development and clinical studies [13]. The gene discussed is FOLH1; the disease is Familial prostate cancer.